BioMarin Pharmaceutical Cash Flow Statement
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical free cash flow
In fiscal 2025, BioMarin Pharmaceutical generated $828.0 million of operating cash flow and spent $103.0 million on capital expenditures. That left free cash flow of $725.0 million, a free-cash-flow margin of 22.5% of revenue. Free cash flow was up 48.7% from the prior year's $487.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 348.90M | 426.86M | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M | -77.21M | -117.04M | -630.21M |
| Net Income growth (YoY) | -18.26% | +154.62% | +18.43% | — | -107.50% | — | — | — | — | — |
| Depreciation & Amortization | 79.56M | 96.43M | 104.39M | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M | 87.86M | 96.91M |
| Stock-Based Compensation | 181.41M | 201.57M | 207.10M | 196.31M | 197.26M | 189.71M | 159.87M | 148.82M | 140.26M | 134.64M |
| Change in Working Capital | -263.98M | -138.92M | -255.06M | -84.35M | 42.87M | -214.24M | -65.19M | -30.72M | -70.84M | -174.61M |
| Operating Cash Flow | 827.99M | 572.84M | 159.26M | 175.90M | 304.54M | 85.36M | 48.26M | 20.21M | -8.76M | -227.84M |
| Capital Expenditures | -103.04M | -85.42M | -96.69M | -120.96M | -95.58M | -114.31M | -145.03M | -144.62M | -199.22M | -148.38M |
| Investing Cash Flow | -414.24M | 136.49M | -111.24M | -20.03M | -366.31M | -53.62M | -31.03M | 264.35M | -305.46M | -484.05M |
| Share Repurchases | — | — | — | 0 | 0 | -50.00M | 0 | 0 | — | — |
| Financing Cash Flow | -42.39M | -526.45M | -18.73M | -18.65M | -48.00K | 181.12M | -74.67M | -388.01M | 507.14M | 727.11M |
| Net Change in Cash | 368.84M | 187.72M | 30.60M | 137.25M | -61.88M | 211.71M | -56.54M | -104.05M | 189.70M | 11.29M |
| Free Cash Flow | 724.96M | 487.42M | 62.57M | 54.94M | 208.96M | -28.95M | -96.76M | -124.41M | -207.98M | -376.22M |
This table shows 10 annual periods of BioMarin Pharmaceutical's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a cash flow statement?